News

Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications

Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn’s disease, a severe and treatment-refractory form of the…

2 years ago

Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference

CHATHAM, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today…

2 years ago

MedAvail to Report First Quarter 2023 Financial Results on May 18

Management to host investor conference call and webcast at 4:30pm EDT todayPHOENIX, May 18, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings,…

2 years ago

Breckenridge Distillery Announces Limited Edition Bourbon Collaboration With Flaviar For Father’s Day

Flaviar, America’s Largest Whiskey Club, Will Exclusively Launch Breckenridge Distillery’s Dad’s Stash Limited Reserve Blend Breckenridge Distillery’s Dad’s Stash Limited…

2 years ago

Alimera Acquires U.S. Commercial Rights to YUTIQ®

Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023 Alimera projects at least $100 million of consolidated…

2 years ago

EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties

–$75M paid at closing with an additional $7.5M payable in equal quarterly installments in 2024 – All outstanding bank debt…

2 years ago

PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy

- CONNECT1-EDO51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of PGN-EDO51 in patients with…

2 years ago

ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata

The Phase 2a, proof-of-concept study, called FAST-AA (FArudodstat STudy in Alopecia Areata), will enroll approximately 60 adult patients in the…

2 years ago

Prelude Therapeutics Announces Pricing of Public Offering

WILMINGTON, Del., May 18, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude" or the "Company") (Nasdaq: PRLD), a clinical-stage precision…

2 years ago